New Jersey Chapter of AACE 11th Annual Meeting

PRINCETON, NJ US
October 6, 2018

Welcome, and thank you for attending the New Jersey Chapter of AACE 11th Annual Meeting & Symposium.

The New Jersey Chapter of AACE program committee has worked very hard to provide a relevant activity for the practicing clinical physician and other healthcare providers seeking education with an emphasis in endocrine disease.

This program has been planned to provide pertinent scientific and clinical information to help you achieve the best solutions in the diagnosis and therapeutic management of patients presenting with endocrine disease. Attendees will obtain updates in not only common and uncommon endocrine disorders, but also newer treatment modalities.

Providing exceptional patient care requires continuing high quality education. The American Association of Clinical Endocrinologists (AACE) was founded in 1991 by a visionary group of leaders to serve as the active voice for clinical endocrinologists. The impetus behind AACE's efforts has always been quality and cost-effective patient care for those with endocrine diseases and disorders. We hope that you will find this program of great value to you in your practice.

http://syllabus.aace.com/2018/Chapters/New_Jersey/index.html

Target Audience

Endocrinologists, MDs & DOs, advanced practice clinicians and other healthcare professionals interested in the treatment of endocrine disease living or working in New Jersey.

Learning Objectives

  1. After participating in a pre-meeting assessment tool, attendees will be able to recognize areas of potential shortcoming and strive to improve knowledge and consequential healthcare practices.
  2. Discuss the epidemiology, prevalence, and risk factors for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
  3. Review use of non-invasive technology available to evaluate the severity of liver disease
  4. Discuss available and emerging treatments for NASH
  5. Describe the clinical manifestations of abnormal reductions in adipose tissue mass
  6. Recognize the pathogenic mechanisms mediating lipoatrophy-associated metabolic abnormalities
  7. Discuss the therapeutic options to manage lipoatrophic diabetes
  8. Recognize the challenges that must be met to automate control of blood glucose levels in people with type 1 diabetes
  9. List the elements of an automated closed-loop bionic pancreas
  10. Describe the results of recent clinical studies of closed-loop blood glucose control using subcutaneous delivery of insulin and glucagon.
  11. Describe the gut hormone responses to diet-induced weight loss
  12. Describe the gut hormone responses to bariatric surgery
  13. Describe changes in hypothalamic hormones that regulate appetite after weight loss
  14. Describe the mechanistic basis for the efficacy of tyrosine kinase inhibitors in the treatment of thyroid cancer
  15. Review current accepted uses of tyrosine kinase inhibitors in the treatment of thyroid cancer
  16. Provide an update on potential new uses for tyrosine kinase inhibitors in the treatment of thyroid cancer
  17. Discuss the 3 clinical phenotypes of Primary Hyperparathyroidism
  18. Review the skeletal manifestations of Primary Hyperparathyroidism
  19. Review the approach to diagnosis, evaluation, and intervention
  20. Understanding how proper documentation is linked to quality, optimal and appropriate E&M coding.
  21. Conceptualize how the E&M documentation correlates to the quality payment program and ACO payments
  22. The importance of ICD coding relative to E&M, QPP and ACO Optimization
  23. At the conclusion of the meeting, attendees will be able to measure learning that occurred that will enable the use of new healthcare techniques and practices and to review or confirm existing care modalities.
Additional information
Available for MOC Points?: 
No
Practice Area: 
Diabetes
Obesity
Thyroid
Course summary
Available credit: 
  • 5.50 AMA
  • 5.50 Attendance
Course opens: 
10/06/2018
Course expires: 
10/07/2019
Event starts: 
10/06/2018 - 8:00am
Event ends: 
10/06/2018 - 8:00pm
Cost:
$0.00

PROGRAM AGENDA

WESTIN PRINCETON
AT FORRESTAL VILLAGE
201 VILLAGE BOULEVARD
PRINCETON, NJ 08540

Saturday, October 6, 2018

8:00 – 8:45 AM

Registration and Continental Breakfast

8:45 – 9:00 AM

Welcoming Remarks & Pre-Meeting Assessment

9:00 – 10:00 AM

NAFLD and NASH Treatment 2018 and Beyond: Cutting through the fat
Dina Halegoua-DeMarzio, MD
Objectives

  1. Discuss the epidemiology, prevalence, and risk factors for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
  2. Review use of non-invasive technology available to evaluate the severity of liver disease
  3. Discuss available and emerging treatments for NASH
10:00 – 11:00 AM

Lipoatrophic Diabetes: What can zebras teach us about horses?
Ranganath Muniyappa, MD, PhD
Objectives

  1. Describe the clinical manifestations of abnormal reductions in adipose tissue mass
  2. Recognize the pathogenic mechanisms mediating lipoatrophy-associated metabolic abnormalities
  3. Discuss the therapeutic options to manage lipoatrophic diabetes
11:00 – 11:30 AM

Break

11:30 – 12:30 PM

The Bionic Pancreas – Non-CME
Edward Damiano, PhD
Objectives

  1. Recognize the challenges that must be met to automate control of blood glucose levels in people with type 1 diabetes
  2. List the elements of an automated closed-loop bionic pancreas
  3. Describe the results of recent clinical studies of closed-loop blood glucose control using subcutaneous delivery of insulin and glucagon.
12:30 – 12:45 PM

NJ AACE Business Meeting

12:45 – 1:45 PM

Lunch

1:45 – 2:45 PM

Obesity/Bariatric Surgery
Judith Korner, MD, PhD
Objectives

  1. Describe the gut hormone responses to diet-induced weight loss
  2. Describe the gut hormone responses to bariatric surgery
  3. Describe changes in hypothalamic hormones that regulate appetite after weight loss
2:45 – 3:15 PM

Break

3:15 – 4:15 PM

The Established and Emergent Roles of Tyrosine Kinase Inhibitors in Thyroid Cancer
Loren Michel, MD
Objectives

  1. Describe the mechanistic basis for the efficacy of tyrosine kinase inhibitors in the treatment of thyroid cancer
  2. Review current accepted uses of tyrosine kinase inhibitors in the treatment of thyroid cancer
  3. Provide an update on potential new uses for tyrosine kinase inhibitors in the treatment of thyroid cancer
4:15 – 5:15 PM

Primary Hyperparathyroidism, 2018
John Bilezikian, MD, MACE
Objectives

  1. Discuss the 3 clinical phenotypes of Primary Hyperparathyroidism
  2. Review the skeletal manifestations of Primary Hyperparathyroidism
  3. Review the approach to diagnosis, evaluation, and intervention
5:15 – 5:30 PM

Post-Meeting Assessment

5:30 – 8:00 PM

Session / Dinner

5:30 – 6:30 PM

Optimal Coding for Optimal Reimbursement and Quality Reporting – Non-CME
Douglas Jorgensen, DO, CPC, FAAO, FACOFP, CAQ
Objectives

  1. Understanding how proper documentation is linked to quality, optimal and appropriate E&M coding.
  2. Conceptualize how the E&M documentation correlates to the quality payment program and ACO payments
  3. The importance of ICD coding relative to E&M, QPP and ACO Optimization
6:30 – 8:00 PM

Panel Discussion

8:00 PM

Adjourn

WESTIN PRINCETON AT FORRESTAL VILLAGE
201 VILLAGE BOULEVARD
PRINCETON, NJ 08540
United States

John P. Bilezikian, MD
Silberberg Professor of Medicine
Vice Chair: International Education and Research
Chief, Emeritus, Division of Endocrinology
Director, Metabolic Bone Diseases Unit
College of Physicians and Surgeons
Columbia University
New York, NY

Edward Damiano, PhD
Professor of Biomedical Engineering at Boston University
President & CEO, Beta Bionics
Boston, MA

Dina Halegoua-De Marzio, MD
Assistant Professor of Medicine
Director, Jefferson Fatty Liver Center
Transplant Hepatology Fellowship Program Director
Sidney Kimmel Medical College at Thomas Jefferson University
Philadelphia, PA

Douglas J Jorgensen, DO, CPC, FAAO, FACOFP, CAQ
Pain Medicine
Principal/CEO Patient
Manchester, ME

Judith Korner, MD, PhD
Professor of Medicine
Director, Weight Control Center
Columbia University Medical Center
Vice-Chair, American Board of Obesity Medicine
New York, NY

Loren Michel, MD
Associate Attending
Head and Neck Medical Oncology
Memorial Sloan Kettering Cancer Center
Middleton, NJ

Ranganath Muniyappa, MD, PhD
Director, NIH Inter-Institute Endocrinology Training Program
Senior Clinician, Diabetes, Endocrinology, and Obesity Branch
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH, Bethesda, MD

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Association of Clinical Endocrinologists (AACE) and the New Jersey Chapter of AACE. The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association of Clinical Endocrinologists (AACE) designates this live activity for a maximum of 5.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 5.50 AMA
  • 5.50 Attendance

Accreditation Period

Course opens: 
10/06/2018
Course expires: 
10/07/2019

Price

Cost:
$0.00
Please login or register to take this course.